Vor Bio completes enrollment in Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis

• Vor Bio completed enrollment in its global Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis.
• Topline results have not been presented; the 24-week primary endpoint readout remains scheduled for the first half of 2027.
• The study aims to show telitacicept can deliver sustained symptom control with a differentiated B-cell modulation approach.
• A separate global Phase 3 registrational trial in ocular myasthenia gravis is planned, with first patient dosing expected in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080700PRIMZONEFULLFEED9821937) on September 08, 2026, and is solely responsible for the information contained therein.